NEUROKININ

Introduction and Definition of Neurokinins

Neurokinins represent a crucial and highly complex family of neuropeptides that function as potent neurotransmitters and neuromodulators within the mammalian nervous system. They are classified biochemically as members of the larger tachykinin family, unified by a common C-terminal amino acid sequence (Phe-X-Gly-Leu-Met-NH2), which is essential for binding to their specific receptors. Neurokinins are released primarily by neurons in both the Central Nervous System (CNS) and the Peripheral Nervous System (PNS), orchestrating a vast array of physiological and neurological processes. These functions span fundamental biological controls, including the modulation of pain signaling, the initiation and perpetuation of inflammation, the regulation of smooth muscle activity, and the complex control of mood and stress responses. Understanding the neurokinin system is central to modern neuroscience, as it provides key insights into the interface between the nervous, endocrine, and immune systems.

The core function of neurokinins is their modulatory role, often acting slower and having more diffuse effects compared to classical, fast-acting neurotransmitters like glutamate or GABA. They typically exert their influence through the activation of specific G protein-coupled receptors (GPCRs), leading to long-lasting changes in neuronal excitability and cellular function. The three primary mammalian neurokinins—Substance P (SP), Neurokinin A (NKA), and Neurokinin B (NKB)—each demonstrate distinct tissue distribution patterns and preferences for specific receptor subtypes (NK1, NK2, and NK3, respectively). This intricate system of ligands and receptors allows for highly specialized signaling pathways that regulate diverse bodily systems, from sensory perception in the dorsal horn of the spinal cord to autonomic control in the enteric nervous system.

Furthermore, the definition of neurokinins emphasizes their integral role in maintaining homeostasis and responding to challenge. For instance, in times of tissue injury or stress, neurokinins are rapidly released from nerve endings, initiating local responses such as vasodilation and plasma extravasation—hallmarks of neurogenic inflammation. This dual localization and function—acting both within the CNS to process information and peripherally to coordinate physical responses—highlights why the neurokinin system is a promising target for therapeutic intervention across numerous disciplines, including pain management, gastroenterology, and psychiatry. Their close relationship with other regulatory peptides, such as Calcitonin Gene-Related Peptide (CGRP), often sees them co-released from the same nerve terminals, suggesting coordinated action in complex physiological cascades.

Historical Context and Discovery

The history of neurokinin discovery began long before the formal identification of the full peptide family, starting with the isolation of Substance P (SP). In the 1930s, Ulf von Euler and John Gaddum, while studying tissue extracts, noted a substance that caused potent contraction of smooth muscle and significant hypotension. They named this extract “Preparation P” due to its powdered nature, which later evolved into Substance P. Initially, its function was unknown, but its potent biological activity suggested a significant regulatory role. Subsequent research throughout the mid-20th century confirmed that SP was localized heavily within sensory nerve fibers, particularly those involved in pain transmission, establishing it as the first identified member of what would become the neurokinin group.

The pivotal shift occurred in the early 1970s and 1980s, driven by advancements in peptide chemistry and molecular biology. Researchers studying nerve fibers and their influence on pain sensation recognized that the effects observed were too diverse to be attributed solely to Substance P. This led to the realization that SP was merely one component of a larger family. The subsequent identification of additional related peptides, specifically Neurokinin A (NKA) and Neurokinin B (NKB), confirmed the existence of the neurokinin family. This discovery was crucial because it provided the necessary molecular diversity to explain the wide range of physiological effects observed in different tissues, paving the way for the classification of specific receptor subtypes tailored to each ligand.

The formal recognition of the neurokinins as a defined family of tachykinins was solidified once their common genetic origins and shared C-terminal structure were elucidated. Substance P and Neurokinin A were found to be encoded by the same gene (the preprotachykinin A gene), illustrating their close biological relationship, while Neurokinin B is encoded by a separate gene (preprotachykinin B). This genetic distinction, alongside their differing affinities for the three primary receptor subtypes (NK1, NK2, and NK3), marked the transition from viewing neurokinin as a singular entity to recognizing it as a complex, multi-component signaling system. This historical progression underscores the importance of ongoing biochemical research in unraveling the true complexity of neuropeptide signaling.

The Tachykinin Family: Key Members

The mammalian neurokinins are fundamentally defined by their membership in the tachykinin peptide family, sharing the highly conserved C-terminal sequence that dictates their receptor binding capabilities. While the three main peptides—SP, NKA, and NKB—share this structural motif, their N-terminal regions vary significantly, conferring distinct receptor selectivity and metabolic stability. This molecular heterogeneity allows the nervous system to utilize these peptides for specialized signaling functions across various organ systems. Substance P is the most intensely studied member, followed by NKA and NKB, each playing a predominant role in specific physiological domains.

Substance P (SP) is perhaps the most widely recognized neurokinin, historically linked to the transmission of pain signals. It is highly concentrated in primary afferent neurons, especially C-fibers, where it is released in the dorsal horn of the spinal cord upon intense noxious stimulation, facilitating nociceptive signaling. SP demonstrates the highest affinity for the Neurokinin 1 (NK1) receptor. Beyond its crucial role in pain perception, SP is heavily involved in mediating stress responses, regulating mood, and driving neurogenic inflammation in the periphery. When released from sensory nerve endings in peripheral tissues, SP acts as a potent mediator, causing mast cell degranulation, smooth muscle contraction, and increasing vascular permeability—essential components of the acute inflammatory response.

Neurokinin A (NKA), often co-released with Substance P from the same precursor molecule, primarily targets the Neurokinin 2 (NK2) receptor. While NKA is found in both the CNS and PNS, its most prominent physiological function is associated with the regulation of smooth muscle contraction, particularly in the airways and the gastrointestinal tract. NKA is a potent bronchoconstrictor, and its aberrant signaling is implicated in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its involvement in the enteric nervous system (ENS) means it plays a critical role in controlling peristalsis and intestinal motility, distinguishing its primary actions from the broader sensory and inflammatory roles of SP.

Neurokinin B (NKB) exhibits the highest selectivity for the Neurokinin 3 (NK3) receptor. Unlike SP and NKA, NKB is predominantly found within the CNS, particularly in brain regions critical for neuroendocrine function, such as the hypothalamus. NKB has emerged as a crucial regulator of reproductive physiology, acting as part of the KNDy (Kisspeptin, Neurokinin B, and Dynorphin) neuronal network. This network is pivotal in controlling the pulsatile release of Gonadotropin-Releasing Hormone (GnRH), thereby governing fertility and sexual maturation. Furthermore, NKB and the NK3 receptor system are increasingly recognized for their roles in regulating temperature homeostasis, mood, and certain psychiatric conditions, underscoring its centralized function in brain signaling.

Neurokinin Receptors and Signal Transduction

The physiological actions of neurokinins are mediated entirely through their corresponding receptors, which belong to the superfamily of G protein-coupled receptors (GPCRs). There are three primary mammalian neurokinin receptor subtypes: NK1, NK2, and NK3. These receptors possess seven transmembrane domains and typically couple to Gq proteins, leading to the activation of phospholipase C (PLC) and the subsequent generation of intracellular signaling molecules, including inositol triphosphate (IP3) and diacylglycerol (DAG). This cascade ultimately results in the mobilization of intracellular calcium stores, which underlies the diverse biological effects of neurokinins, such as neurotransmitter release, muscle contraction, and gene expression changes.

The NK1 receptor is the most widely distributed and extensively studied neurokinin receptor, showing a high affinity for Substance P. It is abundant in the dorsal horn of the spinal cord, the brainstem, and cortical regions, aligning with its roles in pain, mood, and stress. A key characteristic of the NK1 receptor signaling pathway is its rapid and prolonged internalization upon ligand binding. After SP binds, the SP-NK1 complex is endocytosed into the cell, which is thought to be a mechanism for sustaining the signaling effect long after the peptide has dissociated. This slow return of the receptor to the cell surface contributes to the long-lasting and often intense effects of SP in processes like chronic pain and chemotherapy-induced nausea and vomiting (CINV).

The NK2 receptor is primarily activated by Neurokinin A, though it can be weakly activated by Substance P. This receptor is highly concentrated in smooth muscle tissues throughout the body, including the bronchi, bladder, and gastrointestinal tract. Its coupling predominantly involves Gq proteins, leading to robust calcium influx and subsequent muscle contraction. Due to its peripheral localization and specific role in muscle tone, the NK2 receptor is a primary target when investigating treatments for smooth muscle disorders, particularly those related to hyperactivity or spasm, such as irritable bowel syndrome (IBS) or certain cardiovascular conditions.

The NK3 receptor exhibits a strong preference for Neurokinin B and is predominantly expressed in the CNS, especially in the hypothalamus, hippocampus, and limbic system structures. The NK3 receptor system is vital for central regulatory functions, including temperature control, fluid balance, and the complex regulation of the reproductive axis via GnRH neurons. Pharmacologically, antagonists targeting the NK3 receptor have shown promise in manipulating neuroendocrine output, particularly in conditions related to reproductive hormone imbalances, highlighting its central importance in hypothalamic function and neuroendocrine integration.

Physiological Roles in the Central Nervous System (CNS)

Within the CNS, neurokinins are integral modulators of sensory and affective processing. Substance P acts as a principal neurotransmitter in the spinal cord, responsible for transmitting primary nociceptive (pain) signals from the periphery to the central processing centers. When painful stimuli activate sensory afferent fibers, SP is released in the dorsal horn, facilitating the synaptic transmission that alerts the brain to injury. The intensity and duration of the pain experience are heavily influenced by the persistence of SP signaling through the NK1 receptor, making this pathway a critical target for developing novel analgesics that modulate, rather than simply block, pain transmission.

Beyond pain, neurokinins exert significant influence over mood, anxiety, and stress responses. The NK1 receptor, in particular, is richly expressed in brain regions associated with emotional processing, such as the amygdala and periaqueductal gray matter. High levels of SP signaling have been correlated with enhanced anxiety and depressive symptoms. Consequently, the development of selective NK1 receptor antagonists represented a major advancement in neuropsychopharmacology, demonstrating efficacy in treating major depressive disorder and generalized anxiety disorder, often with a different mechanism of action than traditional SSRIs. This suggests that the neurokinin system plays a foundational role in regulating affective states and emotional resilience.

Furthermore, the neurokinin system contributes significantly to neuroendocrine regulation. As previously mentioned, Neurokinin B (NKB) is a critical component of the hypothalamic system controlling reproduction. NKB neurons, along with Kisspeptin and Dynorphin neurons, form a coordinated unit that dictates the pulsatile release of GnRH. Disruption of NKB signaling can lead to significant reproductive dysfunction, emphasizing its non-redundant role in maintaining the delicate hormonal balance necessary for fertility. This central neuroendocrine function underscores the far-reaching influence of neurokinins beyond simple sensory transmission.

Neurokinins also interact deeply with processes related to neuroinflammation and neuroprotection. While SP release is often associated with promoting inflammation following injury (e.g., traumatic brain injury or stroke), other studies suggest that controlled neurokinin signaling may be necessary for neuronal survival and plasticity. The complex interplay between neurokinins and glial cells (astrocytes and microglia) determines whether the outcome of injury is repair or chronic inflammation, indicating that the effects of neurokinins are highly context-dependent within the delicate neural milieu.

Functions in the Peripheral Nervous System and Inflammation

The peripheral nervous system (PNS) is where neurokinins, especially Substance P, exert their most dramatic effects related to local defense and homeostasis, primarily through the mechanism known as neurogenic inflammation. Upon activation of peripheral sensory nerve endings (e.g., due to heat, chemical irritation, or mechanical damage), SP is released antidromically, meaning it travels backwards from the central terminal to the peripheral terminal. Once released locally, SP interacts with NK1 receptors on blood vessels and mast cells, initiating a cascade that involves potent vasodilation, increased capillary permeability (leading to edema), and the release of inflammatory mediators like histamine from mast cells. This rapid, localized response is essential for initiating the healing process and attracting immune cells to the site of injury.

In the gastrointestinal system, neurokinins are crucial regulators of the enteric nervous system (ENS), often referred to as the body’s “second brain.” Both SP (acting via NK1) and NKA (acting via NK2) are widely distributed throughout the gut wall, controlling the rhythmic contractions of smooth muscle necessary for peristalsis and regulating intestinal secretion. Imbalances in neurokinin activity are strongly implicated in functional gastrointestinal disorders (FGIDs), such as Irritable Bowel Syndrome (IBS), where dysregulated motility and heightened visceral sensitivity are key symptoms. Targeting NK receptors in the gut offers a potential pathway for restoring normal bowel function without widespread systemic side effects.

The respiratory system also relies heavily on neurokinin signaling, particularly NKA acting on the NK2 receptor. NKA is a powerful bronchoconstrictor; its release in the airways can trigger intense narrowing of the bronchial tubes. This mechanism is highly relevant in conditions of airway hyperresponsiveness, such as asthma, where exposure to allergens or irritants leads to excessive neurokinin release and subsequent airway constriction. Therapeutic strategies aimed at blocking the NK2 receptor could potentially offer relief by dampening this exaggerated smooth muscle response in the lungs.

Crucially, neurokinins form a direct communication link between the nervous system and the immune system, establishing the neuro-immune axis. Immune cells, including lymphocytes, macrophages, and dendritic cells, express neurokinin receptors. SP, in particular, can influence immune cell proliferation, cytokine release, and migration. This interaction suggests that neurokinins not only initiate inflammation passively but actively modulate the immune response, influencing the trajectory of chronic inflammatory and autoimmune diseases. This complex cross-talk highlights the integrative role of neurokinins in total body health and disease pathogenesis.

Clinical Relevance and Therapeutic Targets

The widespread and potent biological activities of neurokinins have positioned their receptors as highly attractive targets for drug development, particularly the NK1 receptor due to its involvement in pain and affective disorders. One of the most significant clinical successes of neurokinin antagonism is in the treatment of Chemotherapy-Induced Nausea and Vomiting (CINV). Highly emetogenic chemotherapy agents trigger the release of Substance P in the brainstem, specifically in the nucleus tractus solitarius and the area postrema (the chemoreceptor trigger zone). NK1 receptor antagonists, such as aprepitant and fosaprepitant, effectively block this central SP signaling pathway, providing a crucial component of modern antiemetic regimens and significantly improving the quality of life for cancer patients undergoing treatment.

In the field of psychiatry, NK1 receptor antagonists were extensively explored for the treatment of depression and anxiety, based on preclinical evidence showing SP’s role in stress exaggeration. While initial clinical trials showed mixed results for major depressive disorder compared to established treatments, the concept validated the neurokinin system as a viable target for affective disorders. The development trajectory demonstrated the complexity of translating preclinical findings to clinical efficacy, yet it confirmed that modulating NK1 signaling impacts core neurological mechanisms governing mood, further solidifying the link between neurokinins and emotional regulation.

Beyond CINV and psychiatric applications, neurokinin receptor antagonists are being investigated for chronic pain management, particularly neuropathic pain that is refractory to standard opioid or NSAID treatments. Since SP is central to pain transmission, blocking the NK1 receptor offers a strategy to interrupt the chronic sensitization loop that perpetuates neuropathic pain signals. Similarly, antagonists targeting the NK2 and NK3 receptors hold promise for peripheral disorders: NK2 antagonists for respiratory hyperreactivity (asthma) and gastrointestinal motility disorders (IBS), and NK3 antagonists for controlling hot flashes associated with menopause, leveraging their central role in thermoregulation and neuroendocrine signaling.

Conclusion and Future Directions

Neurokinins, comprising Substance P, Neurokinin A, and Neurokinin B, represent a highly conserved and critical family of neuropeptides that integrate sensory information, coordinate inflammatory responses, and modulate complex central nervous system functions, including mood and reproductive control. Their actions, mediated through the specific G protein-coupled receptors (NK1, NK2, and NK3), define crucial pathways in both health and disease. The evidence strongly supports their involvement in processes ranging from acute pain transmission and neurogenic inflammation to chronic conditions like asthma, IBS, and affective disorders.

The successful clinical application of NK1 receptor antagonists in managing chemotherapy-induced nausea and vomiting highlights the therapeutic potential locked within this system. However, the development of highly selective, orally bioavailable antagonists that can effectively cross the blood-brain barrier remains a challenging area of research, particularly for CNS-targeted applications like depression and chronic neuropathic pain. Future research is focused not only on improving antagonist specificity but also on exploring the potential of agonists or modulators that could restore neurokinin function in deficiency states, thereby broadening the therapeutic landscape.

Ultimately, the study of neurokinins continues to deepen our understanding of the fundamental neuro-immune axis, providing molecular mechanisms for how the nervous system communicates with and regulates the immune response. As research progresses, particularly in dissecting the specific roles of NKA (NK2) and NKB (NK3) in peripheral and central homeostasis, the neurokinin system is poised to yield new targets for highly personalized medicine aimed at treating some of the most complex and debilitating physiological and psychiatric disorders.

References

• Arrang, J. M., Garbarg, M., & Pollard, H. (1983). Neurokinins: A family of tachykinins with neurogenic activity. Trends in Pharmacological Sciences, 4(2), 61–65. https://doi.org/10.1016/0165-6147(83)90105-7
• Ghebrehiwet, B., & Mochizuki, H. (2000). Neurokinin receptors: From structure to function. Journal of Neurochemistry, 75(3), 811–821. https://doi.org/10.1046/j.1471-4159.2000.0750811.x
• Kumar, S., & Gupta, S. (2011). Neurokinin B and its Receptor. Current Neuropharmacology, 9(3), 372–384. https://doi.org/10.2174/157015911796437232
• Mantyh, P. W. (2002). Neurokinin receptors and their antagonists in pain and inflammation. Trends in Neurosciences, 25(10), 517–524. https://doi.org/10.1016/S0166-2236(02)02264-2
• Pintar, J. E., & Schaffer, A. E. (2014). Neurokinin B and its receptor: Signaling and function in the CNS. Progress in Neurobiology, 115, 126–140. https://doi.org/10.1016/j.pneurobio.2013.12.001